David Hodl

Head of Sales, Cell Therapy Custom and Configured Platforms • Invetech

David has over 23 years of experience in product commercialization and business development roles. Prior to joining Invetech David led the Cell Processing business unit of SynGen, commercializing equipment and single-use consumables for manufacturing cell-based therapies. He also spent eight years in a business development role with Becton Dickinson’s Corporate Innovation Center, focusing on commercialization of cell-based and next-generation sequencing technologies. David earned an MBA from North Carolina State University and a BA in biology from Linfield College

Also Speaking

Fernanda Masri

Head of Manufacturing Innovation • Cell and Gene Therapy Catapult

Timothy D. Hunt

Chief Executive Officer • Alliance for Regenerative Medicine

Robert Newman

Chief Scientific Officer • Fujifilm Irvine Scientific

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.